MGO One Seven LLC Purchases 4,231 Shares of Gilead Sciences, Inc. $GILD

MGO One Seven LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 31.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,858 shares of the biopharmaceutical company’s stock after purchasing an additional 4,231 shares during the quarter. MGO One Seven LLC’s holdings in Gilead Sciences were worth $2,662,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in GILD. PFS Partners LLC boosted its stake in Gilead Sciences by 101.1% during the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 96 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in Gilead Sciences during the 2nd quarter valued at approximately $25,000. Laurel Wealth Advisors LLC purchased a new position in Gilead Sciences during the 3rd quarter valued at approximately $29,000. Kimelman & Baird LLC purchased a new position in Gilead Sciences during the 2nd quarter valued at approximately $25,000. Finally, Toth Financial Advisory Corp increased its stake in Gilead Sciences by 85.5% in the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 100 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Down 1.7%

Shares of NASDAQ:GILD opened at $167.47 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 0.95 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $175.65. The company has a 50-day moving average price of $151.77 and a 200 day moving average price of $140.25. The company has a market cap of $207.72 billion, a price-to-earnings ratio of -53.00 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same quarter last year, the business posted $2.47 earnings per share. The firm’s revenue was up 6.8% on a year-over-year basis. As a group, equities research analysts predict that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain broadly upbeat, with several recent price-target increases, including targets as high as $200. Coverage cites Gilead’s recent execution, HIV franchise and pipeline; a separate estimate of fair value also moved higher. Gilead price target raised to $200 Gilead fair-value estimate
• Positive Sentiment: Gilead plans to present results from more than 50 studies, including late-breaking clinical data and real-world evidence, at HIV Glasgow 2026 on November 8–11. The updates could offer pipeline and franchise catalysts. Gilead HIV Glasgow presentation
• Positive Sentiment: BioNTech said it advanced a planned Phase 3 trial, pending regulatory approval, combining its candidate pumitamig with Gilead’s cancer drug Trodelvy in triple-negative breast cancer. This represents potential progress for Gilead’s oncology collaboration, though the study remains subject to approval. BioNTech quarterly results and update
• Negative Sentiment: Investors bought 16,499 GILD put options, about 107% above typical volume. The jump may signal increased hedging or bearish positioning, although options activity alone does not establish a market view.
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions. Both sales were made under a prearranged Rule 10b5-1 plan, which may temper their significance, but insider selling can still be viewed cautiously by investors. CEO share sale details

Analysts Set New Price Targets

Several brokerages have recently issued reports on GILD. Citigroup upped their price objective on Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Needham & Company LLC set a $175.00 target price on Gilead Sciences in a research report on Friday. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their target price for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Morgan Stanley boosted their price target on shares of Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $169.74.

Insiders Place Their Bets

In other news, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $169.74, for a total transaction of $2,546,100.00. Following the transaction, the chief executive officer owned 551,683 shares of the company’s stock, valued at approximately $93,642,672.42. The trade was a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the transaction, the director directly owned 12,894 shares in the company, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 126,881 shares of company stock worth $19,252,455. 0.30% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.